DaVita Inc.
NYSE:DVAMedical - Care Facilities
+$1.60 today
- Market cap
- $10.18B
- Beta
- 0.91
- P/E (TTM)
- 18.2
- EPS (TTM)
- $11.60
Volume 1.12M
Average 0.84M
DVA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
DaVita Inc.NYSE: DVA
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables turns positive
Q2 FY2026 accounts receivables was $5.55M, compared with -$133.17M a year earlier. Trailing-twelve-month accounts receivables was $53.62M. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Accounts receivables amounted to 1.5% of revenue in FY2025, up 1.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $5.55M or moves back toward the trailing-twelve-month quarterly average of $13.4M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (210.63M) USD
- Year-over-year change
- -607.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (210.63M) | -607.6% |
| FY2024 | 2024-12-31 | (29.77M) | -117.3% |
| FY2023 | 2023-12-31 | 172.36M | +216.2% |
| FY2022 | 2022-12-31 | (148.39M) | -7.4% |
| FY2021 | 2021-12-31 | (138.14M) | — |
Accounts Receivables vs competitors
How DVA compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +142.9% is the highest of 3, against a peer median of -51.5%.
- Accounts receivables amounts to 0.4% of revenue for DVA, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $96M USD | +21.5% | +40.1% | 0.8% | |
| LTM Jun 2026 | €93.4M EUR | -124.5% | +12.4% | 0.5% | |
| LTM Jun 2026 | $53.62M USD | +142.9% | +12.4% | 0.4% | |
| Peer median (excluding DVA) | — | -51.5% | +26.3% | 0.7% | |
Competitors are the stored peer set for DVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.21B | 781.64M | 691.54M | 1.25B | 1.08B |
| Depreciation & Amortization | 680.62M | 732.6M | 745.44M | 723.86M | 715.35M |
| Deferred Income Tax | 60.48M | (75.67M) | (39.35M) | (57.84M) | 86.57M |
| Stock-Based Compensation | 102.21M | 95.43M | 112.38M | 102.79M | 139.95M |
| Change in Working Capital | (140.64M) | 101K | 194.54M | (29.82M) | (263.24M) |
| Accounts Receivables | (138.14M) | (148.39M) | 172.36M | (29.77M) | (210.63M) |
| Inventory | 5.72M | (757K) | (32.13M) | 17.94M | (19.95M) |
| Accounts Payables | (30.32M) | 87.48M | 26.89M | 1.7M | 128.3M |
| Other Working Capital | 22.1M | 61.77M | 27.42M | (19.7M) | (160.96M) |
| Other Non-Cash Items | 16.45M | 30.47M | 354.5M | 32.31M | 129.15M |
| Operating Cash Flow | 1.93B | 1.56B | 2.06B | 2.02B | 1.89B |
| Capital Expenditures | (641.47M) | (603.43M) | (567.99M) | (555.44M) | (575.86M) |
| Acquisitions (Net) | (200.97M) | (89.19M) | (26.39M) | (251.27M) | (144.5M) |
| Purchases of Investments | (33.84M) | (133.39M) | (322.95M) | (24.46M) | (22.44M) |
| Sales of Investments | 27.88M | 74.91M | 110M | 27.2M | 52.14M |
| Other Investing Activities | 63.66M | 120.76M | 35.52M | 32.54M | 35.71M |
| Investing Cash Flow | (784.73M) | (630.35M) | (771.8M) | (771.43M) | (654.95M) |
| Debt Repayment | 754.26M | (11.28M) | (552.62M) | 1.11B | 769.62M |
| Common Stock Issued | 0 | 18.58M | 16.9M | 20.45M | 23.29M |
| Common Stock Repurchased | (1.6B) | (802.23M) | (272.22M) | (1.39B) | (1.79B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (238.59M) | (326.2M) | (362.56M) | (560.56M) | (374.69M) |
| Financing Cash Flow | (1.08B) | (1.12B) | (1.17B) | (816.94M) | (1.37B) |
| Effect of Forex Changes | (10.01M) | (29.07M) | 8.91M | (18.48M) | 21.15M |
| Net Change in Cash | 53.17M | (215.97M) | 125.65M | 415.19M | (122.08M) |
| Free Cash Flow | 1.29B | 961.14M | 1.49B | 1.47B | 1.31B |
DaVita Inc.
NYSE:DVA
Intrinsic Alpha fair value
Locked
Current Price
$161.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.